P131 Belimumab in the treatment of 38 portuguese SLE patients: a real-life multicentric study. (23rd March 2020)

• Record Type: Journal Article
• Authors: Fernandes, Bruno; Bernardes, Miguel; Barreira, Sofia; Fonseca, João Eurico; Cunha, Margarida; Santos, Maria José; Gonçalves, Nuno; Fernandes, Ana Lúcia; Rodrigues, Joana; Fontes, Tomás; Costa, Lúcia
• Is Part Of: Lupus science & medicine. Volume 7(2020)Supplement 1
• Page Start: A93
• Page End: A93
• Publication Date: 2020-03-23
• Subjects: Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2020-eurolupus.175
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Background: Belimumab, an anti-BLyS monoclonal antibody, is the first biologic available for SLE treatment. We studied its effectiveness and safety in clinical practice. Methods: Multicentric cohort study of SLE patients, fulfilling the 2012 SLICC classification criteria, treated with belimumab in rheumatology departments and registered in the Portuguese registry Reuma.pt . Results: Thirty-eight patients were included: 37 (97.4%) female, aged 46.2±13.9 years, mean disease duration of 11.9±8.6 years. The reasons for prescribing belimumab were: multiorgan involvement in 20 (52.6%), haematologic disorders in 9 (23.7%), cutaneous manifestations in 5 (13.0%), arthritis in 3 (7.9%), necrotizing vasculitis in 1 (2.6%). Belimumab was administered intravenously for a mean of 22.3±20.3 months. SRI response was achieved in 14/27 (51.9%), 12/20 (60%) and 11/12 (91.7%) at 6, 12 and 24 months of belimumab treatment, respectively. Mean SLEDAI significantly decreased from 8.2±3.9 at baseline to 3.8±2.2, 4.1±3.2 and 3.1±1.6 at 6, 12 and 24 months, respectively. Anti-dsDNA antibodies significantly decreased at 6, 12 and 24 months and C3 increased at 12 months of belimumab (table 1 ). We found a significant reduction in mean daily prednisolone dosage (p<0.001) from baseline (10.8±5.1 mg) to the last evaluation under belimumab (5.5±3.0 mg). Eleven (28.9%) patients discontinued belimumab: loss of effectiveness in 4, lost to follow-up in 4, adverse events in 3 (urinary tract infections, acute myocardial infarction, breast cancer). Three presented infections related to belimumab. Conclusions: We confirmed belimumab effectiveness and safety in real-life active SLE patients.